Literature DB >> 3123210

Distribution of seizure types in an epileptic population.

T Keränen1, M Sillanpää, P J Riekkinen.   

Abstract

The distribution of seizure types was investigated in an epidemiological survey of 1,220 patients over 15 years of age. Classification of clinically dominant seizure type according to the International Classification of Epileptic Seizures (ICES) was possible in 1,005 cases (82.5%). Fifty-six percent of patients had partial seizures and 26.5% had generalized seizures. Subclassification of partial seizures revealed simple partial seizures (SPS) in 7.5% of the cases, complex partial seizures (CPS) in 23%, and partial secondarily generalized seizures (PSGS) in 25.5% of the cases. Simple partial onset was seen in 56% of the patients with CPS, and impairment of consciousness at the onset occurred in the remaining 44%. PSGS started with simple partial onset in 92% of the cases and the remaining 8% started with a complex partial phase. Tonic-clonic seizures were the most common type of generalized seizures, accounting for 23% of all and 88% of generalized seizures. Absence seizures were seen in 1% of the cases. A single seizure type was observed in 737 patients (60%) and the remaining 40% had multiple seizure types. SPS, CPS, and absence seizures were most commonly combined with other seizure types. The study revealed that distribution of seizure type varies as a function of age. Although the present study finds ICES relevant, difficulties in its utilization in epidemiological context are demonstrated.

Entities:  

Mesh:

Year:  1988        PMID: 3123210     DOI: 10.1111/j.1528-1157.1988.tb05089.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  11 in total

1.  Partial seizures presenting as panic attacks.

Authors:  S A Thompson; J S Duncan; S J Smith
Journal:  BMJ       Date:  2000-10-21

2.  Inferring evoked brain connectivity through adaptive perturbation.

Authors:  Kyle Q Lepage; ShiNung Ching; Mark A Kramer
Journal:  J Comput Neurosci       Date:  2012-09-19       Impact factor: 1.621

3.  Slow Spatial Recruitment of Neocortex during Secondarily Generalized Seizures and Its Relation to Surgical Outcome.

Authors:  Louis-Emmanuel Martinet; Omar J Ahmed; Kyle Q Lepage; Sydney S Cash; Mark A Kramer
Journal:  J Neurosci       Date:  2015-06-24       Impact factor: 6.167

Review 4.  Treating epilepsy in the elderly: safety considerations.

Authors:  S Arroyo; G Kramer
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

Review 5.  Can anticonvulsant drug therapy "cure" epilepsy?

Authors:  M J Eadie
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

Review 6.  Advances in the application of technology to epilepsy: the CIMIT/NIO Epilepsy Innovation Summit.

Authors:  Steven C Schachter; John Guttag; Steven J Schiff; Donald L Schomer
Journal:  Epilepsy Behav       Date:  2009-09       Impact factor: 2.937

7.  Optimal control based seizure abatement using patient derived connectivity.

Authors:  Peter N Taylor; Jijju Thomas; Nishant Sinha; Justin Dauwels; Marcus Kaiser; Thomas Thesen; Justin Ruths
Journal:  Front Neurosci       Date:  2015-06-03       Impact factor: 4.677

8.  Optogenetic delay of status epilepticus onset in an in vivo rodent epilepsy model.

Authors:  Inna Sukhotinsky; Alexander M Chan; Omar J Ahmed; Vikram R Rao; Viviana Gradinaru; Charu Ramakrishnan; Karl Deisseroth; Ania K Majewska; Sydney S Cash
Journal:  PLoS One       Date:  2013-04-24       Impact factor: 3.240

9.  Importance of Video-EEG Monitoring in the Diagnosis of Refractory Panic Attacks.

Authors:  Batool F Kirmani; Diana Mungall
Journal:  Case Rep Psychiatry       Date:  2013-07-24

10.  The quality of life among Sudanese patients with epilepsy, Khartoum, Sudan.

Authors:  Etedal A Ahmed Ibrahim; Lina Hussain Mustafa Ali; Khabab Abbasher Hussien Mohamed Ahmed; Mohammed Eltahier Abdalla Omer; Ibrahim M Mahgoub; Mazin Salah-Eldien Hassan Haroun; Moez Mohammed Ibrahim Bashir
Journal:  Brain Behav       Date:  2022-01-18       Impact factor: 2.708

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.